Bear, the first bullet point that Zack's makes regarding the length is:

• The population that has enrolled in the study has a much lower than expected event rate overall,

From what I recall when this issue was addressed to Resverlogix I thought their response was that the overall incidence rate for the trial was tracking as planned at 9%. If my recall is correct this would rule out Zack's first hypothesis.

Unless there is another factor not expressed then point 2 seems to be reasonable...yes...no?

Toinv